利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

38 条记录 (耗时 0.049 秒)

    Water soluble cellulose etherified derivatives styptic materials
    9.
    发明授权
    Water soluble cellulose etherified derivatives styptic materials 有权
    水溶性纤维素醚化衍生物苯乙烯类物质

    公开(公告)号：US07262181B2

    公开(公告)日：2007-08-28

    申请号：US10476559

    申请日：2001-04-30

    申请人： Mei Zhang ,  Jinyu Zhang ,  Xia Song

    发明人： Mei Zhang ,  Jinyu Zhang ,  Xia Song

    IPC分类号： A61K31/717 ,  C08B11/12

    CPC分类号： C08B11/12 ,  A61L15/28 ,  A61L2400/04 ,  C08B15/00 ,  C08L1/26

    摘要： The present invention relates to hemostatic materials made of water-soluble cellulose ether derivatives, such as methylcellulose, ethylcellulose, hydroxyethylcellulose, and pharmaceutically acceptable salts of carboxymethylcellulose, especially to hemostatic materials made of water-soluble cellulose ether derivatives capable of being absorbed in live body. The present invention also relates to the use of water-soluble cellulose hemostatic materials for the preparation of internal and external hemostatic articles and pharmaceutical compositions, and hemostatic articles and pharmaceutical compositions thereof.

    摘要翻译： 本发明涉及由水溶性纤维素醚衍生物如甲基纤维素，乙基纤维素，羟乙基纤维素和羧甲基纤维素的药学上可接受的盐形成的止血材料，特别是由能够吸收在活体中的水溶性纤维素醚衍生物制成的止血材料 。 本发明还涉及水溶性纤维素止血材料用于制备内部和外部止血制品和药物组合物以及止血制品及其药物组合物的用途。

    Compounds acting at the centrosome
    10.
    发明申请
    Compounds acting at the centrosome 审中-公开
    作用于中心体的化合物

    公开(公告)号：US20060167106A1

    公开(公告)日：2006-07-27

    申请号：US11283570

    申请日：2005-11-18

    申请人： Mei Zhang ,  Andras Ladanyi

    发明人： Mei Zhang ,  Andras Ladanyi

    IPC分类号： A61K31/16 ,  C07C327/40

    CPC分类号： G01N33/5035 ,  A61K31/00 ,  A61K31/16 ,  A61K31/165 ,  A61K39/02 ,  A61K45/06 ,  G01N33/5008 ,  G01N33/5011 ,  G01N33/502 ,  G01N33/6875 ,  G01N2800/382 ,  A61K2300/00

    摘要： The present invention relates to compounds, and methods utilizing compounds, which exhibit one or more of the following properties: i) disrupts organization of an actin cytoskeleton of a cell; ii) disrupts organization of a microtubule network of a cell; iii) induces accumulation of tubulin at centrosomes but does not induce accumulation of tubulin in a nucleus of a cell; iv) induces accumulation of tubulin at centrosomes at a concentration of 500 nM or less within four hours; v) induces accumulation of Hsp70 and has weak-to-moderate proteasome inhibitory activity; and vi) does not have proteasome inhibitory activity when assayed on purified proteasomes.

    摘要翻译： 本发明涉及化合物和利用化合物的方法，其具有以下一个或多个性质：i）破坏细胞的肌动蛋白细胞骨架的组织; ii）破坏细胞微管网络的组织; iii）诱导微管蛋白在中心体的积累，但不诱导微管蛋白在细胞核中的积累; iv）在四小时内以500nM或更小的浓度诱导中心体上的微管蛋白积累; v）诱导Hsp70的积累并具有弱至中度的蛋白酶体抑制活性; 和vi）在纯化的蛋白酶体上测定时不具有蛋白酶体抑制活性。